Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bicalutamide
Drug ID BADD_D00271
Description Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Indications and Usage For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
Marketing Status approved
ATC Code L02BB03
DrugBank ID DB01128
KEGG ID D00961
MeSH ID C053541
PubChem ID 2375
TTD Drug ID D0V9BD
NDC Product Code 49711-1504; 49711-1509; 51846-1028; 62559-890; 71205-577; 0904-6019; 53104-7664; 16714-816; 60429-177; 62559-680; 43265-7195; 46014-1111; 82920-004; 54893-0001; 16729-023; 58623-0068; 63629-8308; 15308-0360; 47335-485
UNII A0Z3NAU9DP
Synonyms bicalutamide | 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide | Casodex | Cosudex | ICI-176334 | ICI 176334
Chemical Information
Molecular Formula C18H14F4N2O4S
CAS Registry Number 90357-06-5
SMILES CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Syncope02.11.04.015; 17.02.04.008; 24.06.02.0120.004218%
Systemic lupus erythematosus10.04.03.004; 15.06.02.003; 23.03.02.0060.002812%-
Tachypnoea22.02.01.0140.001406%-
Tenderness08.01.08.005---
Tension19.06.02.005---
Testicular atrophy05.05.02.004; 21.13.01.0010.001406%-
Thrombocytopenia01.08.01.0020.013358%-
Thrombophlebitis24.01.02.001---
Tooth abscess07.09.01.003; 11.01.04.003---
Tooth loss07.09.09.001; 12.01.17.0260.001406%-
Torsade de pointes02.03.04.0050.004921%-
Transient ischaemic attack17.08.04.001; 24.04.06.0050.007030%
Tumour lysis syndrome14.05.01.004; 16.32.03.0020.001406%
Urethral disorder20.07.01.002---
Urinary incontinence17.05.01.008; 20.02.02.010--
Urinary retention20.02.02.0110.004921%
Urinary tract disorder20.08.01.001---
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Ventricular extrasystoles02.03.04.0070.001406%-
Ventricular fibrillation02.03.04.0080.002812%
Ventricular tachycardia02.03.04.0100.001406%
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Yellow skin08.01.03.046; 09.01.01.009; 23.03.03.042---
Tubulointerstitial nephritis20.05.02.0020.004921%-
General physical health deterioration08.01.03.0180.003515%-
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages